Suchergebnisse - "Bosteels, Cedric"

PubPharm (39)

1

A Complement Atlas identifies interleukin 6 dependent alternative pathway dysregulation as a key druggable feature of COVID-19

enthalten in: bioRxiv.org | 2024

von Van Damme, K. | Hoste, L. | Declercq, J. | +17

2

A complement atlas identifies interleukin-6-dependent alternative pathway dysregulation as a key druggable feature of COVID-19

enthalten in: Science translational medicine | 2023

von Van Damme, K. | Hoste, L. | Declercq, J. | +20

3

LXR signaling controls homeostatic dendritic cell maturation

enthalten in: Science immunology | 2023

von Bosteels, V. | Maréchal, S. | De Nolf, C. | +25

4

LXR signaling controls homeostatic dendritic cell maturation

enthalten in: Science immunology | 12 May 2023

von Bosteels, V. | Maréchal, S. | De Nolf, C. | +25

5

Loss of GM-CSF-dependent instruction of alveolar macrophages in COVID-19 provides a rationale for inhaled GM-CSF treatment

enthalten in: Cell reports. Medicine | 2022

von Bosteels, C. | Van Damme, K. | De Leeuw, E. | +30

6

Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19 : an open-label randomized controlled trial

enthalten in: Respiratory research | 2022

von De Leeuw, E. | Van Damme, K. | Declercq, J. | +25

7

Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

enthalten in: Respiratory research | 2022

von De Leeuw, E. | Van Damme, K. | Declercq, J. | +25

8

Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with Covid-19: an open-label randomized controlled trial

enthalten in: ResearchSquare.com | 2022

von De Leeuw, E. | Damme, K. | Declercq, J. | +25

9

Prospective longitudinal evaluation of hospitalised COVID-19 survivors 3 and 12 months after discharge

enthalten in: ERJ open research | 2022

von Lorent, N. | Vande Weygaerde, Y. | Claeys, E. | +22

10

TIM3+ TRBV11-2 T cells and IFNγ signature in patrolling monocytes and CD16+ NK cells delineate MIS-C

enthalten in: The Journal of experimental medicine | 2022

von Hoste, L. | Roels, L. | Naesens, L. | +80